Latest Strategy News

Fat Prophets Global Contrarian Fund Ltd reported a dramatic turnaround with a $9.3 million profit for the half-year ended December 2025, up from just $14,000 a year earlier, alongside a declared interim dividend.

Brisbane Broncos Limited has reported a robust 2025 financial year, with profit before tax soaring 35% to $11.34 million, buoyed by premiership wins in both the NRL and NRLW competitions. The club also declared a special dividend, reflecting its strong commercial and community momentum.

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

CONNEQT Health reported a 40% revenue increase to $2.28 million for the half-year ending December 2025, driven by strong sales of its CONNEQT Pulse device and early subscription uptake. Despite narrowing its net loss by 14%, the company continues to navigate operational restructuring and funding challenges as it pivots towards a recurring revenue model.

Insignia Financial Ltd shareholders are invited to vote on a $4.80 per share acquisition scheme by Daintree BidCo, an entity backed by CC Capital Partners LLC and affiliates. The Federal Court has approved the Scheme Meeting and the distribution of the Scheme Booklet, which includes an Independent Expert’s Report supporting the fairness and reasonableness of the offer.

DigitalX Limited reported a narrower half-year loss and increased revenues, underpinned by a strategic pivot to a Bitcoin-first treasury model and operational cost discipline.

Verbrec Limited has reported a remarkable turnaround in its half-year results, posting a $9 million net profit and announcing its first interim dividend in the current period. Strategic acquisitions and a sharp rise in net tangible assets underpin this strong performance.

Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.

Energy Technologies Limited reported a $5.63 million net loss for the half-year ending December 2025, with revenue down 53% as the company restructures and refocuses on renewable energy markets. Significant debt refinancing and board changes mark a critical phase for the industrial cable manufacturer.

Racura Oncology reported a $4.1 million loss for H1 FY26, reflecting heavy investment in clinical trials and intellectual property. The company also boosted cash reserves through capital raises and rebranded from Race Oncology.

De.mem Limited reported a 20% increase in revenue to $29.9 million for FY2025, alongside a reduced net loss and its first full-year positive adjusted EBITDA. The company also completed the acquisition of Core Chemicals, expanding its specialty chemicals footprint in the gold mining sector.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.